Cowen $AMRN:
-PT raised to $10

-Q1 Vascepa sales to reach $150M (vs. Street's $130M)

-Appeal will be filed in early May

-Most $ = sale and CVR (value based on EU exclusivity)

-Potential B/O targets are $MRK, $PFE, $AZN due to prior EU presence and building of CV portfolio